nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Tretinoin—peripheral nervous system neoplasm	0.124	0.318	CbGbCtD
Vardenafil—CYP3A5—Vincristine—peripheral nervous system neoplasm	0.0569	0.146	CbGbCtD
Vardenafil—CYP3A5—Etoposide—peripheral nervous system neoplasm	0.0521	0.134	CbGbCtD
Vardenafil—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.052	0.133	CbGbCtD
Vardenafil—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0483	0.124	CbGbCtD
Vardenafil—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0222	0.0569	CbGbCtD
Vardenafil—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0203	0.0522	CbGbCtD
Vardenafil—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.0139	0.0356	CbGbCtD
Vardenafil—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000406	0.000775	CcSEcCtD
Vardenafil—Headache—Tretinoin—peripheral nervous system neoplasm	0.000406	0.000774	CcSEcCtD
Vardenafil—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000406	0.000774	CcSEcCtD
Vardenafil—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000404	0.000771	CcSEcCtD
Vardenafil—Pain—Vincristine—peripheral nervous system neoplasm	0.000404	0.000771	CcSEcCtD
Vardenafil—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.000404	0.000771	CcSEcCtD
Vardenafil—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000403	0.000769	CcSEcCtD
Vardenafil—Rash—Melphalan—peripheral nervous system neoplasm	0.000403	0.000769	CcSEcCtD
Vardenafil—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000403	0.000768	CcSEcCtD
Vardenafil—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000401	0.000765	CcSEcCtD
Vardenafil—Chest pain—Etoposide—peripheral nervous system neoplasm	0.0004	0.000762	CcSEcCtD
Vardenafil—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000399	0.000761	CcSEcCtD
Vardenafil—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000399	0.000761	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000397	0.000757	CcSEcCtD
Vardenafil—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000395	0.000753	CcSEcCtD
Vardenafil—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000395	0.000753	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000393	0.00075	CcSEcCtD
Vardenafil—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000391	0.000745	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.00039	0.000744	CcSEcCtD
Vardenafil—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00039	0.000744	CcSEcCtD
Vardenafil—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000388	0.00074	CcSEcCtD
Vardenafil—Nausea—Topotecan—peripheral nervous system neoplasm	0.000388	0.000739	CcSEcCtD
Vardenafil—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000387	0.000737	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—peripheral nervous system neoplasm	0.000387	0.000737	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000385	0.000735	CcSEcCtD
Vardenafil—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000385	0.000734	CcSEcCtD
Vardenafil—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000385	0.000734	CcSEcCtD
Vardenafil—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000383	0.000731	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000381	0.000727	CcSEcCtD
Vardenafil—Infection—Etoposide—peripheral nervous system neoplasm	0.000381	0.000726	CcSEcCtD
Vardenafil—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00038	0.000724	CcSEcCtD
Vardenafil—Nausea—Melphalan—peripheral nervous system neoplasm	0.00038	0.000724	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.000722	CcSEcCtD
Vardenafil—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000378	0.00072	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—peripheral nervous system neoplasm	0.000378	0.00072	CcSEcCtD
Vardenafil—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000375	0.000716	CcSEcCtD
Vardenafil—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000374	0.000713	CcSEcCtD
Vardenafil—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000374	0.000713	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.000712	CcSEcCtD
Vardenafil—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000373	0.000711	CcSEcCtD
Vardenafil—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000372	0.00071	CcSEcCtD
Vardenafil—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.00037	0.000706	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.000704	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.000704	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000368	0.000701	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000365	0.000697	CcSEcCtD
Vardenafil—PDE10A—Hemostasis—HGF—peripheral nervous system neoplasm	0.000364	0.00423	CbGpPWpGaD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000364	0.000694	CcSEcCtD
Vardenafil—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000362	0.000691	CcSEcCtD
Vardenafil—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000362	0.00069	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000361	0.000688	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—PTPN11—peripheral nervous system neoplasm	0.000358	0.00416	CbGpPWpGaD
Vardenafil—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000358	0.000683	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.000682	CcSEcCtD
Vardenafil—Pain—Cisplatin—peripheral nervous system neoplasm	0.000358	0.000682	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000357	0.00068	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000355	0.00412	CbGpPWpGaD
Vardenafil—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000352	0.000671	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000349	0.000666	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000349	0.000666	CcSEcCtD
Vardenafil—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000348	0.000664	CcSEcCtD
Vardenafil—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000347	0.000662	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	0.000345	0.000657	CcSEcCtD
Vardenafil—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000345	0.000657	CcSEcCtD
Vardenafil—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000344	0.000656	CcSEcCtD
Vardenafil—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000342	0.000651	CcSEcCtD
Vardenafil—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000341	0.000649	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.00034	0.000649	CcSEcCtD
Vardenafil—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000339	0.000647	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000339	0.00393	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PPP3R1—peripheral nervous system neoplasm	0.000338	0.00393	CbGpPWpGaD
Vardenafil—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000337	0.000642	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000337	0.000642	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—PTPN11—peripheral nervous system neoplasm	0.000337	0.00391	CbGpPWpGaD
Vardenafil—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000337	0.000642	CcSEcCtD
Vardenafil—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000336	0.00064	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—PTPN11—peripheral nervous system neoplasm	0.000335	0.00389	CbGpPWpGaD
Vardenafil—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000334	0.000636	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—NTRK1—peripheral nervous system neoplasm	0.000333	0.00387	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—PTPN11—peripheral nervous system neoplasm	0.000333	0.00387	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—PTPN11—peripheral nervous system neoplasm	0.000332	0.00385	CbGpPWpGaD
Vardenafil—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000331	0.000631	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.00033	0.00383	CbGpPWpGaD
Vardenafil—Pain—Etoposide—peripheral nervous system neoplasm	0.000328	0.000625	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000327	0.000624	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000325	0.00377	CbGpPWpGaD
Vardenafil—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000325	0.000619	CcSEcCtD
Vardenafil—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000324	0.000617	CcSEcCtD
Vardenafil—Sweating—Epirubicin—peripheral nervous system neoplasm	0.000323	0.000616	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—peripheral nervous system neoplasm	0.000321	0.000612	CcSEcCtD
Vardenafil—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.00032	0.00372	CbGpPWpGaD
Vardenafil—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	0.000319	0.000608	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000607	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.000318	0.000606	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000316	0.00367	CbGpPWpGaD
Vardenafil—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000602	CcSEcCtD
Vardenafil—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000316	0.000602	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000314	0.0006	CcSEcCtD
Vardenafil—PDE1B—G Protein Signaling Pathways—NRAS—peripheral nervous system neoplasm	0.000314	0.00365	CbGpPWpGaD
Vardenafil—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000313	0.000597	CcSEcCtD
Vardenafil—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000313	0.000596	CcSEcCtD
Vardenafil—PDE1B—DAP12 interactions—PTPN11—peripheral nervous system neoplasm	0.000312	0.00362	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—PTPN11—peripheral nervous system neoplasm	0.000312	0.00362	CbGpPWpGaD
Vardenafil—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000312	0.000595	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000312	0.00362	CbGpPWpGaD
Vardenafil—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000594	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000312	0.000594	CcSEcCtD
Vardenafil—PDE1B—Innate Immune System—PPP3R1—peripheral nervous system neoplasm	0.000311	0.00361	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00031	0.0036	CbGpPWpGaD
Vardenafil—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000309	0.00059	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR—PTPN11—peripheral nervous system neoplasm	0.000309	0.00359	CbGpPWpGaD
Vardenafil—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000309	0.00059	CcSEcCtD
Vardenafil—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000308	0.000588	CcSEcCtD
Vardenafil—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000307	0.000586	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—PTPN11—peripheral nervous system neoplasm	0.000307	0.00356	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000305	0.00354	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—PTPN11—peripheral nervous system neoplasm	0.000305	0.00354	CbGpPWpGaD
Vardenafil—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000304	0.000579	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000303	0.000578	CcSEcCtD
Vardenafil—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.000303	0.000578	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000577	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000302	0.000576	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	0.000301	0.000574	CcSEcCtD
Vardenafil—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000301	0.000573	CcSEcCtD
Vardenafil—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.0003	0.000572	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.0003	0.000572	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000299	0.00057	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000569	CcSEcCtD
Vardenafil—Rash—Vincristine—peripheral nervous system neoplasm	0.000298	0.000569	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000298	0.00346	CbGpPWpGaD
Vardenafil—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000298	0.000568	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—peripheral nervous system neoplasm	0.000297	0.000566	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000566	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000296	0.000565	CcSEcCtD
Vardenafil—Headache—Vincristine—peripheral nervous system neoplasm	0.000296	0.000565	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000295	0.000562	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.000294	0.00056	CcSEcCtD
Vardenafil—PDE6G—Disease—ENO2—peripheral nervous system neoplasm	0.000293	0.0034	CbGpPWpGaD
Vardenafil—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000557	CcSEcCtD
Vardenafil—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000291	0.000556	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000291	0.000555	CcSEcCtD
Vardenafil—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000286	0.000546	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000283	0.00329	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—ERBB2—peripheral nervous system neoplasm	0.000283	0.00329	CbGpPWpGaD
Vardenafil—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000539	CcSEcCtD
Vardenafil—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000282	0.000538	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—peripheral nervous system neoplasm	0.000282	0.000537	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000282	0.00327	CbGpPWpGaD
Vardenafil—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000536	CcSEcCtD
Vardenafil—Nausea—Vincristine—peripheral nervous system neoplasm	0.000281	0.000536	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000281	0.00326	CbGpPWpGaD
Vardenafil—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000535	CcSEcCtD
Vardenafil—Flushing—Epirubicin—peripheral nervous system neoplasm	0.00028	0.000535	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000535	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.00028	0.000533	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000531	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000278	0.000529	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—PTPN11—peripheral nervous system neoplasm	0.000276	0.00321	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000276	0.00321	CbGpPWpGaD
Vardenafil—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000527	CcSEcCtD
Vardenafil—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000275	0.000524	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000524	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000274	0.000523	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000274	0.000523	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000521	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000272	0.000519	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000271	0.00315	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000271	0.00315	CbGpPWpGaD
Vardenafil—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000271	0.000517	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000269	0.000514	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—ERBB2—peripheral nervous system neoplasm	0.000266	0.00309	CbGpPWpGaD
Vardenafil—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000266	0.000507	CcSEcCtD
Vardenafil—PDE5A—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000266	0.00308	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000266	0.00308	CbGpPWpGaD
Vardenafil—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000265	0.000505	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—ERBB2—peripheral nervous system neoplasm	0.000265	0.00307	CbGpPWpGaD
Vardenafil—Rash—Cisplatin—peripheral nervous system neoplasm	0.000264	0.000503	CcSEcCtD
Vardenafil—PDE1B—Signaling by ERBB2—ERBB2—peripheral nervous system neoplasm	0.000263	0.00306	CbGpPWpGaD
Vardenafil—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000263	0.000502	CcSEcCtD
Vardenafil—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000502	CcSEcCtD
Vardenafil—PDE1B—DAP12 signaling—ERBB2—peripheral nervous system neoplasm	0.000262	0.00304	CbGpPWpGaD
Vardenafil—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000262	0.0005	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000498	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.000497	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000495	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.000495	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000259	0.00301	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000257	0.00298	CbGpPWpGaD
Vardenafil—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000254	0.000485	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000254	0.000484	CcSEcCtD
Vardenafil—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000253	0.000483	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	0.000253	0.000482	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000482	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.000481	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000251	0.00291	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.00025	0.0029	CbGpPWpGaD
Vardenafil—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000248	0.000474	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000248	0.000473	CcSEcCtD
Vardenafil—PDE1B—Immune System—CD55—peripheral nervous system neoplasm	0.000248	0.00288	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—ERBB2—peripheral nervous system neoplasm	0.000247	0.00286	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—ERBB2—peripheral nervous system neoplasm	0.000247	0.00286	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000246	0.00286	CbGpPWpGaD
Vardenafil—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000245	0.000467	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR—ERBB2—peripheral nervous system neoplasm	0.000244	0.00284	CbGpPWpGaD
Vardenafil—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000244	0.000466	CcSEcCtD
Vardenafil—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000244	0.000464	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000464	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—ERBB2—peripheral nervous system neoplasm	0.000242	0.00281	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000242	0.00281	CbGpPWpGaD
Vardenafil—Rash—Etoposide—peripheral nervous system neoplasm	0.000242	0.000461	CcSEcCtD
Vardenafil—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000241	0.00046	CcSEcCtD
Vardenafil—PDE1B—Signaling by PDGF—ERBB2—peripheral nervous system neoplasm	0.000241	0.0028	CbGpPWpGaD
Vardenafil—Headache—Etoposide—peripheral nervous system neoplasm	0.00024	0.000458	CcSEcCtD
Vardenafil—PDE1B—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000239	0.00278	CbGpPWpGaD
Vardenafil—PDE1B—Disease—GNS—peripheral nervous system neoplasm	0.000239	0.00277	CbGpPWpGaD
Vardenafil—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000237	0.000452	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000237	0.00275	CbGpPWpGaD
Vardenafil—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000236	0.000451	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000236	0.00274	CbGpPWpGaD
Vardenafil—PDE6G—Disease—SLC2A1—peripheral nervous system neoplasm	0.000236	0.00274	CbGpPWpGaD
Vardenafil—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000236	0.00045	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.000449	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.000446	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000233	0.000443	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000231	0.000441	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000231	0.00268	CbGpPWpGaD
Vardenafil—PDE1B—G Protein Signaling Pathways—HRAS—peripheral nervous system neoplasm	0.00023	0.00267	CbGpPWpGaD
Vardenafil—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.000438	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000228	0.000435	CcSEcCtD
Vardenafil—Nausea—Etoposide—peripheral nervous system neoplasm	0.000228	0.000434	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000226	0.000431	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000427	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000427	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000427	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000223	0.000426	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000222	0.000424	CcSEcCtD
Vardenafil—PDE6G—Signaling by Wnt—MYC—peripheral nervous system neoplasm	0.000222	0.00258	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000222	0.00257	CbGpPWpGaD
Vardenafil—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000221	0.000422	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.00022	0.000419	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000219	0.00255	CbGpPWpGaD
Vardenafil—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000418	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000219	0.000417	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—ERBB2—peripheral nervous system neoplasm	0.000218	0.00254	CbGpPWpGaD
Vardenafil—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000218	0.000416	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—NRAS—peripheral nervous system neoplasm	0.000215	0.0025	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IFNB1—peripheral nervous system neoplasm	0.000215	0.0025	CbGpPWpGaD
Vardenafil—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.00041	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000215	0.00041	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000215	0.00249	CbGpPWpGaD
Vardenafil—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000214	0.000408	CcSEcCtD
Vardenafil—Infection—Epirubicin—peripheral nervous system neoplasm	0.000213	0.000407	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—PTPN11—peripheral nervous system neoplasm	0.000213	0.00247	CbGpPWpGaD
Vardenafil—Shock—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000403	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—peripheral nervous system neoplasm	0.000211	0.000402	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000211	0.000402	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.00021	0.0004	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000209	0.000398	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000208	0.000396	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000395	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000395	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000395	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000394	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000206	0.000393	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000205	0.000391	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.000387	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—NRAS—peripheral nervous system neoplasm	0.000202	0.00235	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—NRAS—peripheral nervous system neoplasm	0.000201	0.00234	CbGpPWpGaD
Vardenafil—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000383	CcSEcCtD
Vardenafil—PDE1B—Signaling by ERBB2—NRAS—peripheral nervous system neoplasm	0.0002	0.00233	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—NRAS—peripheral nervous system neoplasm	0.000199	0.00232	CbGpPWpGaD
Vardenafil—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000379	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000198	0.0023	CbGpPWpGaD
Vardenafil—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.000376	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000196	0.000373	CcSEcCtD
Vardenafil—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000373	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000195	0.000372	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000194	0.00226	CbGpPWpGaD
Vardenafil—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000194	0.00037	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000194	0.00037	CcSEcCtD
Vardenafil—PDE1B—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000194	0.00225	CbGpPWpGaD
Vardenafil—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000193	0.000368	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000193	0.000368	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000192	0.000366	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000365	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.000191	0.000364	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000189	0.00036	CcSEcCtD
Vardenafil—PDE1B—Immune System—CD34—peripheral nervous system neoplasm	0.000188	0.00218	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—NRAS—peripheral nervous system neoplasm	0.000188	0.00218	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—NRAS—peripheral nervous system neoplasm	0.000188	0.00218	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—NRAS—peripheral nervous system neoplasm	0.000186	0.00216	CbGpPWpGaD
Vardenafil—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000354	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000185	0.000354	CcSEcCtD
Vardenafil—PDE1B—Hemostasis—HGF—peripheral nervous system neoplasm	0.000185	0.00214	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—NRAS—peripheral nervous system neoplasm	0.000184	0.00214	CbGpPWpGaD
Vardenafil—Pain—Epirubicin—peripheral nervous system neoplasm	0.000184	0.00035	CcSEcCtD
Vardenafil—PDE1B—Signaling by PDGF—NRAS—peripheral nervous system neoplasm	0.000183	0.00213	CbGpPWpGaD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000181	0.000345	CcSEcCtD
Vardenafil—PDE1B—Immune System—PPP3R1—peripheral nervous system neoplasm	0.000181	0.0021	CbGpPWpGaD
Vardenafil—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000343	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—NRAS—peripheral nervous system neoplasm	0.000179	0.00208	CbGpPWpGaD
Vardenafil—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.00034	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000178	0.00206	CbGpPWpGaD
Vardenafil—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000338	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000177	0.000337	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000337	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000176	0.000335	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000175	0.000334	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000173	0.00201	CbGpPWpGaD
Vardenafil—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.000327	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000171	0.00199	CbGpPWpGaD
Vardenafil—Pain—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000324	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.00017	0.000324	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—ERBB2—peripheral nervous system neoplasm	0.000168	0.00195	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000167	0.00194	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PPP3R1—peripheral nervous system neoplasm	0.000167	0.00194	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000166	0.00193	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—NRAS—peripheral nervous system neoplasm	0.000166	0.00193	CbGpPWpGaD
Vardenafil—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000164	0.000312	CcSEcCtD
Vardenafil—CYP3A5—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000163	0.00189	CbGpPWpGaD
Vardenafil—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00031	CcSEcCtD
Vardenafil—PDE1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.00016	0.00186	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—NRAS—peripheral nervous system neoplasm	0.00016	0.00185	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—NRAS—peripheral nervous system neoplasm	0.00016	0.00185	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NCAM1—peripheral nervous system neoplasm	0.00016	0.00185	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000159	0.00184	CbGpPWpGaD
Vardenafil—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000158	0.000302	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—HRAS—peripheral nervous system neoplasm	0.000158	0.00183	CbGpPWpGaD
Vardenafil—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.0003	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000294	CcSEcCtD
Vardenafil—PDE6G—Signaling by Wnt—AKT1—peripheral nervous system neoplasm	0.000154	0.00179	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	0.000152	0.00177	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—CASP3—peripheral nervous system neoplasm	0.000152	0.00177	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000152	0.00177	CbGpPWpGaD
Vardenafil—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000152	0.00029	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	0.000148	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—HRAS—peripheral nervous system neoplasm	0.000148	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—HRAS—peripheral nervous system neoplasm	0.000147	0.00171	CbGpPWpGaD
Vardenafil—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000147	0.00028	CcSEcCtD
Vardenafil—PDE1B—Signaling by ERBB2—HRAS—peripheral nervous system neoplasm	0.000147	0.0017	CbGpPWpGaD
Vardenafil—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000146	0.000279	CcSEcCtD
Vardenafil—PDE1B—DAP12 signaling—HRAS—peripheral nervous system neoplasm	0.000146	0.00169	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000145	0.00169	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000145	0.00168	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ENO2—peripheral nervous system neoplasm	0.000145	0.00168	CbGpPWpGaD
Vardenafil—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000143	0.000272	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000271	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	0.000141	0.00164	CbGpPWpGaD
Vardenafil—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000268	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.00014	0.00163	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—AKT1—peripheral nervous system neoplasm	0.000139	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—peripheral nervous system neoplasm	0.000137	0.00159	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—peripheral nervous system neoplasm	0.000137	0.00159	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—peripheral nervous system neoplasm	0.000137	0.00159	CbGpPWpGaD
Vardenafil—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000137	0.00026	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—peripheral nervous system neoplasm	0.000136	0.00158	CbGpPWpGaD
Vardenafil—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000136	0.000259	CcSEcCtD
Vardenafil—Rash—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000258	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000258	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—peripheral nervous system neoplasm	0.000135	0.00157	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000135	0.00156	CbGpPWpGaD
Vardenafil—Headache—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000257	CcSEcCtD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—peripheral nervous system neoplasm	0.000134	0.00156	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.000133	0.00154	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTPN11—peripheral nervous system neoplasm	0.000132	0.00153	CbGpPWpGaD
Vardenafil—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.000251	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000131	0.00152	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—AKT1—peripheral nervous system neoplasm	0.000131	0.00152	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—AKT1—peripheral nervous system neoplasm	0.00013	0.00151	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	0.00013	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—AKT1—peripheral nervous system neoplasm	0.000129	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—AKT1—peripheral nervous system neoplasm	0.000129	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NRAS—peripheral nervous system neoplasm	0.000128	0.00148	CbGpPWpGaD
Vardenafil—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000243	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000127	0.00148	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000127	0.00147	CbGpPWpGaD
Vardenafil—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000241	CcSEcCtD
Vardenafil—PDE1B—Immune System—IFNB1—peripheral nervous system neoplasm	0.000125	0.00146	CbGpPWpGaD
Vardenafil—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000239	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000239	CcSEcCtD
Vardenafil—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000237	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000122	0.00142	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—peripheral nervous system neoplasm	0.000122	0.00142	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—peripheral nervous system neoplasm	0.000122	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—peripheral nervous system neoplasm	0.000122	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTPN11—peripheral nervous system neoplasm	0.000121	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—AKT1—peripheral nervous system neoplasm	0.000121	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—AKT1—peripheral nervous system neoplasm	0.000121	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—AKT1—peripheral nervous system neoplasm	0.00012	0.00139	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—AKT1—peripheral nervous system neoplasm	0.000119	0.00138	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—AKT1—peripheral nervous system neoplasm	0.000119	0.00138	CbGpPWpGaD
Vardenafil—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000225	CcSEcCtD
Vardenafil—PDE1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000117	0.00136	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000117	0.00136	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—peripheral nervous system neoplasm	0.000117	0.00136	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SLC2A1—peripheral nervous system neoplasm	0.000117	0.00135	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—AKT1—peripheral nervous system neoplasm	0.000116	0.00134	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	0.000111	0.00129	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00011	0.00128	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—AKT1—peripheral nervous system neoplasm	0.000107	0.00125	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ERBB2—peripheral nervous system neoplasm	0.000104	0.00121	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—AKT1—peripheral nervous system neoplasm	0.000103	0.0012	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—AKT1—peripheral nervous system neoplasm	0.000103	0.0012	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	0.000103	0.00119	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	0.000101	0.00117	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HGF—peripheral nervous system neoplasm	9.68e-05	0.00112	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—ERBB2—peripheral nervous system neoplasm	9.58e-05	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—peripheral nervous system neoplasm	9.35e-05	0.00109	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.24e-05	0.00107	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	9.17e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	9.01e-05	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	8.78e-05	0.00102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—AKT1—peripheral nervous system neoplasm	8.26e-05	0.000959	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—peripheral nervous system neoplasm	8.1e-05	0.00094	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.99e-05	0.000927	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GNS—peripheral nervous system neoplasm	7.96e-05	0.000924	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—peripheral nervous system neoplasm	7.94e-05	0.000921	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	7.73e-05	0.000897	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NME1—peripheral nervous system neoplasm	7.63e-05	0.000886	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.58e-05	0.00088	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	7.53e-05	0.000874	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	7.51e-05	0.000872	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MYC—peripheral nervous system neoplasm	7.39e-05	0.000858	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—COX2—peripheral nervous system neoplasm	7.35e-05	0.000853	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	7.32e-05	0.00085	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.31e-05	0.000848	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—peripheral nervous system neoplasm	7.29e-05	0.000846	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	7.25e-05	0.000842	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	7.16e-05	0.000831	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	7.12e-05	0.000827	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTPN11—peripheral nervous system neoplasm	7.06e-05	0.00082	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.71e-05	0.000779	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	6.65e-05	0.000772	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.63e-05	0.00077	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	6.57e-05	0.000763	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.52e-05	0.000757	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTPN11—peripheral nervous system neoplasm	6.52e-05	0.000757	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	6.46e-05	0.00075	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—peripheral nervous system neoplasm	6.19e-05	0.000719	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	6.08e-05	0.000706	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—peripheral nervous system neoplasm	5.92e-05	0.000688	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.92e-05	0.000688	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—peripheral nervous system neoplasm	5.81e-05	0.000674	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.66e-05	0.000657	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB2—peripheral nervous system neoplasm	5.58e-05	0.000648	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.56e-05	0.000645	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.42e-05	0.000629	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—peripheral nervous system neoplasm	5.33e-05	0.000619	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—peripheral nervous system neoplasm	5.23e-05	0.000607	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.18e-05	0.000601	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB2—peripheral nervous system neoplasm	5.15e-05	0.000598	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—peripheral nervous system neoplasm	5.13e-05	0.000595	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.12e-05	0.000594	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—peripheral nervous system neoplasm	5.05e-05	0.000586	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ENO2—peripheral nervous system neoplasm	4.82e-05	0.00056	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—peripheral nervous system neoplasm	4.71e-05	0.000547	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.65e-05	0.00054	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	4.65e-05	0.00054	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	4.57e-05	0.00053	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.45e-05	0.000516	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.25e-05	0.000494	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—peripheral nervous system neoplasm	4.25e-05	0.000493	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—peripheral nervous system neoplasm	4.14e-05	0.000481	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—BCHE—peripheral nervous system neoplasm	4.08e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—peripheral nervous system neoplasm	4.07e-05	0.000472	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.96e-05	0.00046	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.93e-05	0.000456	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—peripheral nervous system neoplasm	3.92e-05	0.000455	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.89e-05	0.000451	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TH—peripheral nervous system neoplasm	3.83e-05	0.000445	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	3.7e-05	0.00043	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—peripheral nervous system neoplasm	3.65e-05	0.000424	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	3.61e-05	0.000419	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.59e-05	0.000417	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	3.55e-05	0.000412	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.5e-05	0.000406	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	3.42e-05	0.000397	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	3.4e-05	0.000395	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.31e-05	0.000384	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.28e-05	0.00038	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—GNAS—peripheral nervous system neoplasm	3.13e-05	0.000363	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—peripheral nervous system neoplasm	3.11e-05	0.000361	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ABCB1—peripheral nervous system neoplasm	3.07e-05	0.000356	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3e-05	0.000349	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—peripheral nervous system neoplasm	2.87e-05	0.000333	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.75e-05	0.000319	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—peripheral nervous system neoplasm	2.74e-05	0.000318	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.56e-05	0.000297	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—peripheral nervous system neoplasm	2.53e-05	0.000294	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	2.24e-05	0.00026	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.1e-05	0.000244	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.01e-05	0.000233	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.9e-05	0.00022	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.81e-05	0.00021	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.78e-05	0.000207	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.77e-05	0.000206	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	1.45e-05	0.000169	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	1.43e-05	0.000166	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—peripheral nervous system neoplasm	8.44e-06	9.8e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	3.93e-06	4.56e-05	CbGpPWpGaD
